leadXpro, first tenant of Park InnovAARE’s innovation campus
One month after the groundbreaking ceremony of Park Innovaare’s new Innovation Campus, leadXpro is the first company to sign a tenancy agreement.
One month after the groundbreaking ceremony of Park Innovaare’s new Innovation Campus, leadXpro is the first company to sign a tenancy agreement.
The in meso in situ serial X-ray crystallization method enables structure determination of very fragile crystals.
leadXpro CEO Michael Hennig contributes a chapter about the progress of structure biology in drug discovery
Lundbeck partners with leadXpro to discover drugs for membrane protein targets by high-resolution X-ray and cryo-Electron Microscopy
Astex Pharmaceuticals partners with leadXpro to facilitate structure-based drug discovery for membrane protein targets by cryo-Electron Microscopy
By licensing cryosparc software and upgrading of its in-house computing capacity, leadXpro enhances its ability for high resolution structure determination of membrane protein drug targets by single particle cryo-Electron Microscopy (cryo-EM)
Two independent structures of CCR2A in complex with the orthosteric antagonist MK-0812 were solved, confirming the importance of residue E2917.39 for antagonist binding. Structural modeling of pyrimidine amide antagonists showed an interaction with the non-conserved H1213.33, leading to a significant selectivity over CCR5, suggesting strategies for highly selective CCR2 antagonist design.
The registration for the International Symposium on Structure Biology for Drug Discovery@SwissFEL on June 25-27, 2019 in Villigen, Switzerland is now open.
leadXpro and Sanofi collaborate for cryo-EM structure project
leadXpro determined the first protein structure at the Swiss Free Electron Laser (SwissFEL) facilities.